Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Kikkoman Biochemifa Company advances global health and safety through precision-driven innovation in biotech and food testing.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    granules-india-limited-m-2025-07-07

    Virtual Booth

    Contact Supplier

    Allsino Pharma excels in R&D & manufacturing of RSMs, GMP intermediates, & APIs; ISO-certified, GMP-compliant, accredited by NMPA.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Menu

    Rifamixin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 232Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Salix Pharmaceuticals Launches Campaign to Educate on Xifaxan
    Salix Pharmaceuticals Launches Campaign to Educate on Xifaxan

    07 Jul 2025

    // ACCESSWIRE

    https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/bausch-healths-gastroenterology-business-salix-pharmaceuticals-launch-1044901

    ACCESSWIRE
    07 Jul 2025
    Share Share
    Zydus gets USFDA nod for Generic IBS-D treatment drug
    Zydus gets USFDA nod for Generic IBS-D treatment drug

    02 Jun 2025

    // ECONOMICTIMES

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/zydus-gets-usfda-nod-for-generic-ibs-d-treatment-drug/articleshow/121567028.cms

    ECONOMICTIMES
    02 Jun 2025
    Share Share
    Xifaxan(R) reduces 30-Day OHE rehospitalization risk
    Xifaxan(R) reduces 30-Day OHE rehospitalization risk

    06 May 2025

    // ACCESSWIRE

    https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/xifaxanr-rifaximin-treatment-following-overt-hepatic-encephalopathy-o-1023754

    ACCESSWIRE
    06 May 2025
    Share Share
    US Court rules in favor of FDA, Salix, Teva, against Norwich
    US Court rules in favor of FDA, Salix, Teva, against Norwich

    17 Apr 2025

    // ACCESSWIRE

    https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/us-district-court-grants-summary-judgment-in-favor-of-fda-salix-and-t-1016430

    ACCESSWIRE
    17 Apr 2025
    Share Share
    Bausch's Xifaxan Chosen For Inflation Reduction Act Medicare
    Bausch's Xifaxan Chosen For Inflation Reduction Act Medicare

    17 Jan 2025

    // ACCESSWIRE

    https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/bausch-health-statement-on-selection-of-xifaxanrifaximin-for-inflation-reduction-acts-medicare-negotiation-program-969865

    ACCESSWIRE
    17 Jan 2025
    Share Share
    Amneal`s Generics Rifaximin Receives Tentative Approval in US
    Amneal`s Generics Rifaximin Receives Tentative Approval in US

    16 Jan 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218862

    FDA
    16 Jan 2025
    Share Share